

(51) International Patent Classification:
A61K 31/225 (2006.01)(21) International Application Number:
PCT/US2011/052318(22) International Filing Date:
20 September 2011 (20.09.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/384,446 20 September 2010 (20.09.2010) US(71) Applicant (for all designated States except US):
KAREUS THERAPEUTICS, SA [CH/CH]; 40 Rue
Fritz-Courvoiser, CH-2300 La Chaux-De-Fonds (CH).


(72) Inventors; and

(75) Inventors/Applicants (for US only): KHANNA, Ish [US/
US]; 520 Barnesley Lane, Alpharetta, Georgia 30022
(US). PILLARISETTI, Sivaram [US/US]; 4762 Grand
Heron Ct, Norcross, Georgia 30092 (US).(74) Agent: GRECI, Marcia; Nelson Mullins Riley & Scar-
borough, LLP, IP Department, 100 North Tryon Street,
42nd Floor, Charlotte, North Carolina 28202-4000 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA



Formula I

(57) **Abstract:** Novel compounds of Formula I are provided: its stereoisomers and/or pharmaceutically acceptable salts for the treatment of diabetes and diabetes-associated dyslipidemia, wherein R¹ is selected from a group consisting of hydroxy, alkoxy, amine, alkyl, haloalkyl, NHSO₂R, or NHCOR wherein R is selected from alkyl or cycloalkyl, NHR' wherein R' is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy; and n¹ and n² are independently selected from 0, 1, and 2. At least one of R³ and R⁴ and/or R⁵ and R⁶ form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO₂. Additionally, when R³ and R⁴ or R⁵ and R⁶ do not form a cyclic ring, then they may be independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl. L₁ is a linear aliphatic chain optionally containing from 4 to 16 carbon atoms. The chain may optionally be substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl. R² is independently selected from hydrogen, alkoxy, hydroxy, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, cyano, or COR⁷, wherein R⁷ is selected from hydroxy, alkyl, alkoxy, or amine, NHR', NHSO₂R, or NHCOR. Y¹ is oxygen or hydrogen. Y² is optional, wherein when Y² is present, Y¹ and Y² are hydrogen. When Y² is not present, Y¹ is a carbonyl group.

